Gland Pharma Quarterly Results for Trading Insights
In Mar 2026, Gland Pharma (GLAND) reported revenue ₹1,854 Cr and net profit ₹367 Cr — revenue +26.2% YoY. Compare with Gland Pharma valuation methods to assess whether the stock is under or overvalued.
GLAND Quarterly Results — Revenue, Profit & EPS Highlights
Gland Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore GLAND price movement history to track price trends across different timeframes.
- Revenue of ₹1,854 Cr in Mar 2026 (+18.0% vs Sept 2025, +26.2% vs Mar 2025)
- Net Profit of ₹367 Cr in Mar 2026 (+99.5% vs Sept 2025, +96.3% vs Mar 2025)
- EBITDA of ₹625 Cr in Mar 2026 (+57.0% vs Sept 2025)
- Operating Margin of 29.0% in Mar 2026 (+8.0pp vs Sept 2025)
- Earnings Per Share of ₹22.26 in Mar 2026 (+99.6% vs Sept 2025)
Gland Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GLAND quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,854 | 1,571 | 1,469 | 1,563 | 1,759 | 18.0% | 26.2% |
| Net Profit (₹ Cr) | 367 | 184 | 187 | 216 | 262 | - | - |
| EBITDA (₹ Cr) | 625 | 398 | 392 | 425 | 474 | - | - |
| EPS (₹) | 22.26 | 11.15 | 11.32 | 13.08 | 15.87 | - | - |
| Operating Margin (%) | 29.0% | 21.0% | 24.0% | 24.0% | 24.0% | - | - |
GLAND Share Price Trend — 1-Year Movement Across Quarterly Results
Gland Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit GLAND share price.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GLAND vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gland Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores